Janux Therapeutics Inc., a clinical-stage biopharmaceutical company, announced the appointment of Janeen Doyle as Chief Corporate and Business Development Officer. With over 24 years of experience in corporate strategy and business development across biotech, pharma, and venture ecosystems, Doyle joins Janux from Flagship Pioneering, where she was a Senior Partner and Senior Vice President. Her extensive background includes roles at Bristol Myers Squibb and Celgene, focusing on strategic collaborations and business development.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.